

## In Vivo Star Anti-Human CD56 (NCAM) Antibody

<b>Catalog Number:</b>	516901, 516902, 516903
<b>Size:</b>	1 mg, 5 mg, 25 mg
<b>Target Name:</b>	human CD56
<b>Regulatory Status:</b>	RUO

### PRODUCT DETAILS

---

<b>Clone:</b>	N901
<b>Application:</b>	Direct ELISA, functional assay, Flow Cytometry
<b>Reactivity:</b>	Human
<b>Format:</b>	Liquid
<b>Product Description:</b>	In vivo Grade Recombinant Anti-human CD56 Monoclonal Antibody
<b>Isotype:</b>	Mouse IgG1 Kappa
<b>Antibody Type:</b>	Recombinant
<b>Purity:</b>	>95% by reducing SDS-PAGE
<b>Endotoxin:</b>	< 1 EU per 1 mg of the protein by the LAL method.
<b>Storage Conditions:</b>	4°C
<b>Grade:</b>	In vivo
<b>Recommended Usage:</b>	This product is suitable in in vitro functional assays or in vivo on human cells used in animal models. Optimal amounts need to be determined empirically for each experiment.
<b>Hidden Synonyms:</b>	InVivoMab, InVivoPlus, GoInVivo, In Vivo Gold

### BACKGROUND INFORMATION

---

CD56, also known as neural cell adhesion molecule (NCAM), is a multifunctional cell surface glycoprotein belonging to the immunoglobulin (Ig) superfamily. While originally characterized in the nervous system, CD56 is best known in immunology as a defining marker of natural killer (NK) cells and a subset of T lymphocytes. Its expression level on NK cells is used to distinguish functionally distinct subsets, most notably CD56bright and CD56dim NK cells.

Structurally, CD56 is a type I transmembrane protein composed of five extracellular Ig-like domains and two fibronectin type III domains, followed by a single transmembrane region and a cytoplasmic tail. Alternative splicing generates several isoforms (primarily NCAM-120, NCAM-140, and NCAM-180), which differ in their cytoplasmic domains and signaling capabilities. CD56 can also be post-translationally modified by polysialylation, a feature that modulates its adhesive properties and is particularly important in neural development.

Functionally, CD56 mediates homophilic interactions (CD56-CD56 binding) as well as heterophilic interactions with other ligands, including heparan sulfate proteoglycans, fibroblast growth factor receptor (FGFR), and components of the extracellular matrix. In

the immune system, CD56 plays a role in cell-cell adhesion, immune synapse formation, and signal transduction. CD56<sup>bright</sup> NK cells are typically less cytotoxic but produce high levels of cytokines such as IFN- $\gamma$ , contributing to immune regulation, whereas CD56<sup>dim</sup> NK cells exhibit potent cytotoxic activity against virally infected and transformed cells.

CD56 is implicated in several diseases. Aberrant or ectopic expression of CD56 is observed in various malignancies, including multiple myeloma, small cell lung carcinoma, neuroendocrine tumors, and certain leukemias and lymphomas. In hematologic diagnostics, CD56 expression is routinely used as an immunophenotypic marker to aid in disease classification and prognosis. For example, CD56 expression in multiple myeloma has been associated with altered patterns of bone marrow adhesion and disease behavior.

Therapeutically, CD56 has emerged as a potential target in oncology. Antibody-based approaches and antibody-drug conjugates directed against CD56 have been explored to selectively eliminate CD56-expressing tumor cells, particularly in neuroendocrine cancers and hematologic malignancies. In addition, CD56 is widely used as a marker for NK cell isolation, monitoring, and quality control in NK cell-based immunotherapies, underscoring its importance in both basic research and clinical applications.

This product is supplied subject to the terms and conditions at [www.innocyto.com/web/terms.php](http://www.innocyto.com/web/terms.php) and may only be used as provided in the stated terms. Products are for Research Use Only.